Platinum in neoadjuvant therapy for triple-negative breast cancer

VernacularTitle:铂类在三阴性乳腺癌新辅助治疗中的应用进展及疗效预测作用
Author: Liulu ZHANG ¹ ; Yuanqi CHEN ; Jiachen ZOU ; Kun WANG
Author Information

1. 广东省人民医院　广东省医学科学院乳腺肿瘤科，广州　510080
Keywords: Triple-negative breast cancer; Neoadjuvant chemotherapy; Platinum; Homologous recombination deficiency
From: Chinese Journal of Endocrine Surgery 2022;16(5):516-519
CountryChina
Language:Chinese
Abstract: Although adding platinum to taxane- and anthracycline-based neoadjuvant chemotherapy regimens for triple-negative breast cancer (TNBC) patients can significantly improve the pathological complete response (pCR) rate and long-term survival, it is associated with higher treatment-related adverse events (AEs) . Current researches focus on the response predictors to select patients who may benefit from platinum-based chemotherapy. Homologous recombination deficiency (HRD) can identify patients who truly need platinum drugs, that is, those with BRCA wild-type but HRD tumors. Results suggest that anthracycline-based chemotherapy is sufficient for BRCA mutation carriers and that non-HRD carriers will not benefit from the added carboplatin.